Shineco Stock Price, News & Analysis

Shineco, Inc. (NASDAQ: SISI) announced organizational changes effective March 25, 2022. Mr. Yuying Zhang resigned as Chairman of the Board, and Mr. Mike Zhao, an existing Board member, was appointed as Chairman. Mr. Xiqiao Liu was appointed to the Board and will also serve as Chief Operating Officer. Zhao brings over 20 years of management experience, while Liu has over 10 years in investment and asset management. CEO Jennifer Zhan expressed gratitude to Zhang and optimism regarding the new appointments, aiming for continued growth and stability in the company.

Shineco, Inc. (NASDAQ: SISI) has entered into a fund establishment cooperation agreement with Beijing Jin Tai Yuan Feng Investment Management Co., Ltd. to create a life science-focused limited partnership fund in Shandong Province, China. JTYF aims to raise RMB200 million for the fund, which will invest in high-growth life science projects. Shineco will participate in the fund's investment committee, facilitating its strategic transition into healthcare and biotechnology sectors. This collaboration aligns with Shineco's goal to develop digital medical care and enhance its market presence.

On March 4, 2022, Shineco, Inc. (NASDAQ: SISI) signed a strategic agreement to develop a city-level tumor classification diagnosis and treatment center in Weifang, China, as part of its Life Science Industrial Park Project. The company plans to invest $500 million, with $100 million allocated to the center, expected to treat 100,000 tumor patients annually. This initiative aligns with China's public service goals and aims to enhance local medical resources, offering advanced diagnostic services at reduced costs, potentially saving patients up to RMB 5 billion in medical expenses.

Shineco, Inc. (NASDAQ: SISI) has launched its redesigned website to enhance user experience and inform stakeholders about its expansion into the life science industry. The modernized site features user-friendly navigation and easy access to corporate information, including management details and SEC filings. CEO Jennifer Zhan emphasized that the website revamp represents a significant step in showcasing the company's latest developments to shareholders and the investment community. This initiative reflects Shineco's commitment to improving brand awareness and market presence.

Shineco, Inc. (NASDAQ: SISI) announced a strategic cooperation agreement with Beijing Xihuan Psychological Consulting Co., Ltd. on February 21, 2022. The partnership aims to establish an industry-university-research-medical collaborative platform focusing on the psychological rehabilitation of tumor patients. Both companies will conduct research on mental health interventions, enhancing Shineco's tumor clinical treatment system. This initiative seeks to improve early diagnosis and treatment rates for tumor diseases by integrating psychological health into comprehensive care.

On February 16, 2022, Shineco, a producer of herbal medicines and biotech products, signed a strategic cooperation agreement with Beijing Jinshengyun Pharmaceutical Technology Co., Ltd. (JSY). The partnership aims to enhance R&D in innovative drugs and medical devices. JSY specializes in clinical trials and regulatory compliance, contributing expertise to the establishment of Shineco's pharmaceutical R&D center. This collaboration aligns with China's healthcare development goals, intending to seize market opportunities in the pharmaceutical industry.

Shineco (SISI) announced a partnership with Weifang Jianyi Medical Devices to jointly manufacture nuclear medicine imaging devices, including PET, PET-CT, and PET-MRI. This collaboration aims to produce up to 100 devices in 2022, each projected to cost between USD $1.10 million and $1.25 million. The partnership will leverage WJM's technological expertise, addressing the high demand for advanced imaging solutions in China, which is currently dominated by foreign firms like GE and Philips. The devices will be distributed to over 100 specialized hospitals for tumor diagnosis in China.

Shineco, Inc. (NASDAQ: SISI) has appointed Professor Qiyin Sun as Chief Medical Consultant to spearhead its tumor treatment research and innovation. Professor Sun, a prominent figure with over 30 years in medical R&D, has notable achievements in nuclear medicine and medical imaging. His expertise includes the development of radiodynamic therapy devices, certified by both the CFDA and FDA. Shineco's CEO, Jennifer Zhan, expressed confidence that Professor Sun's extensive experience will enhance the company’s R&D capabilities, aiming to improve diagnosis and treatment technologies for tumor patients.

Shineco, Inc. (NASDAQ: SISI) has announced its acquisition of a 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd. for approximately $5.6 million, paid with 700,551 shares at $8 each. This strategic move aims to accelerate Shineco's entry into the digital healthcare sector and enhance its services through XPYK's established medical platform. The deal is expected to close within 60 days, pending customary conditions. Shineco plans to leverage this acquisition to improve health management services and capture growth opportunities in China's expanding digital medical market.